Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. It is focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using its drug delivery technologies. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. Its other pipeline drug candidates: GTX-102 and GTX-101. GTX-102 is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia. GTX-101 is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:ACST - Post by User

Bullboard Posts
Post by Rawcolton Apr 25, 2018 10:08am
195 Views
Post# 27937232

Accumulating..

Accumulating..This is a Godsend... I bought initial position at $1.40 now adding my final postion buy. To much potential for the Capre drug. I see a buyout or a double by year end with any kind of phase 3 relults.

This is a billion dollar drug, it will be curious to see what happens with it and in which hands it ends up.

Bullboard Posts